tier helps us know what the priorities are for the diagnostics," commented one respondent. Other participants commented that the EDL is "a quality metric, it gives people the confidence of the quality [of tests]" and "will help in bringing in some standardization in the testing methodology and eventually help in uniform accreditations across countries."
Even though most of the participants welcomed the EDL and saw many benefits, 53% (16/30 participants) had concerns that introduction of the EDL might have some negative consequences. Price capping was a major concern that 40% of the participants (12/30 participants) raised. "If EDL becomes a mechanism to put pressure on pricing or local manufacturing, then it can serve as a disincentive," one participant remarked.
Twenty percent (6/30 participants) expressed concerns that, if the EDL is not updated regularly, then it will not be able to incorporate the latest technologies, thus limiting innovation. The EDL should be a "'living' [document] and updated as much as possible," according to one survey participant. Interestingly, 83% of respondents (25/30 participants) thought that omitting specific company and brand names from the EDL was a good strategy.
The tests listed in the EDL are supported by WHO guidelines or included in the WHO prequalification program for IVDs, when applicable. One participant commented that it takes "money to get WHO approval." WHO endorsement or prequalification is difficult to attain for smaller companies, whose products might ultimately be excluded from the EDL. Another potential concern was that some countries "might be reticent to adopt new technologies so the barriers to enter the market may be higher" for newer companies or products.
Although our survey did not cover all IVD companies, the data suggest that the industry largely welcomes the WHO EDL initiative and agrees that it will help improve access to diagnostics in LMICs. The WHO can use our findings to address some of the concerns raised. To address the need for frequent updates, the WHO has already published a call for applications for the second edition of the EDL, which will be released in 2019. While the WHO EDL does not include any recommendations on pricing, it will be up to LMICs how they adapt and implement the EDL to ensure access. Industry concerns about price controls will need to be balanced by the need for LMICs to make tests affordable and accessible.
